Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
Zacks
More News
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Zacks
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Zacks
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High After Better-Than-Expected Earnings
Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High After Better-Than-Expected Earnings...
MarketBeat
HC Wainwright Reiterates "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)
HC Wainwright reissued a "buy" rating and issued a $310.00 price target on shares of Krystal Biotech in a research note on Monday...
MarketBeat
Krystal Biotech Q1 Earnings Call Highlights
Krystal Biotech (NASDAQ:KRYS) reported first-quarter 2026 net revenue of $116.4 million from global sales of VYJUVEK, supported by continued demand in the U.S. and early traction in Europe and Japan. Management highlighted positive operating leverage, a 95% gross margin, and an expanding clinical pi...